Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody

Zika virus (ZIKV) infection in both infants and adults is associated with neurological complications including, but not limited to, microcephaly and Guillain-Barre syndrome. Antibody therapy can be effective against virus infection. We isolated ZIKV envelope domain III-specific neutralizing antibodies (nAbs) from two convalescent patients with ZIKV infection. One antibody, 2F-8, exhibited potent in vitro neutralizing activity against Asian and American strains of ZIKV. To prevent FcγR-mediated antibody-dependent enhancement, we prepared IgG1 with LALA variation. A single dose of 2F–8 in the context of IgG1 or IgG1-LALA prior to or post lethal ZIKV challenge conferred complete protection in mice. •The human monoclonal antibody 2F-8 showed potent neutralizing activity against Asian and American strains of ZIKV.•A single dose of 2F-8 IgG1 prior to or post exposure to a lethal challenge of ZIKV conferred complete protection in mice.